Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 14;41(19):1801-1803.
doi: 10.1093/eurheartj/ehaa235.

SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?

Gabriela M Kuster  1   2 , Otmar Pfister  1   2 , Thilo Burkard  1   3 , Qian Zhou  1 , Raphael Twerenbold  1   4 , Philip Haaf  1 , Andreas F Widmer  5 , Stefan Osswald  1
Affiliations

SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?

Gabriela M Kuster et al. Eur Heart J. .
No abstract available

PubMed Disclaimer

Figures

Take home figure
Take home figure
Conceptual figure highlighting the central role of ACE2 in the potentially deleterious (red) and protective (green) effects of the RAAS and its inhibition in the development of severe acute respiratory syndrome (SARS). ACE-Is and ARBs increase ACE2 expression and activity (grey) as shown by a few animal and human studies,6,7 but the mechanism has yet to be identified. Although there is currently no evidence, this could theoretically increase viral load and worsen outcome (red). In a reverse causality, ACE2 acts as a gatekeeper of the RAAS by degrading AngII to Ang1-7, hence diminishing its Ang II receptor 1-mediated deleterious effects. Therefore, ACE-I or ARB treatment could theoretically mitigate lung injury (green). Evidence for this mainly stems from animal studies.9,10 Providing soluble recombinant (r)ACE2 (blue) addresses both mechanisms by cell independent binding of SARS-CoV2 and degrading AngII to Ang 1-7. This concept is currently being tested in a pilot study in patients with COVID-19.13
None
See this image and copyright information in PMC

Comment in

References

    1. Sommerstein R, Gräni C.. Rapid response: re: preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. BMJ 2020. https://www.bmj.com/content/368/bmj.m810/rr-2 (8 March 2020).
    1. Dong E, Du H, Gardner L.. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020. https://coronavirus.jhu.edu/map.html (11 March 2020). - PMC - PubMed
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. Epub ahead of print. - PMC - PubMed
    1. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M.. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450–454. - PMC - PubMed
    1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020. Epub ahead of print. - PMC - PubMed